Capecitabine Tablet, Film Coated
Product Images NDC 31722-775

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Capecitabine (NDC 31722-775). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Camber Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Capecitabine150mglabel (Capecitabine150mglabel)

Label for Capecitabine Tablets USP 150 mg film-coated tablets by Camber Pharmaceuticals, Inc. The label indicates hazardous drug warnings, a package quantity of 60 tablets, and provides patient instructions and storage information. Manufactured for Camber Pharmaceuticals and made by Hetero Labs Limited, India. The label includes a barcode and contact information.*

FDA Label Image

Capecitabine500mglabel (Capecitabine500mglabel)

Capecitabine Tablets USP 500 mg film-coated tablets in a bottle label by Camber Pharmaceuticals, Inc. The label indicates 120 tablets per container, identifies the drug as a hazardous, cytotoxic agent, and provides patient instructions including swallowing tablets whole with water within 30 minutes of a meal. Storage instructions and a U.S. contact number are also present.*

FDA Label Image

Capecitabinecamberlogo (Capecitabinecamberlogo)

FDA Label Image

Capecitabinechemicalstructure (Capecitabinechemicalstructure)

Chemical structure of capecitabine, showing its molecular framework with fluorinated pyrimidine and sugar moieties, including an ester side chain with an alkyl group.*

FDA Label Image

Capecitabinefigure1 (Capecitabinefigure1)

A survival curve chart comparing two treatment groups over time in months since randomization. One group received 5-FU plus leucovorin (dashed line) and the other received capecitabine (solid line). The vertical axis represents survival probability, while the horizontal axis shows months since randomization, with patient numbers at risk displayed beneath.*

FDA Label Image

Capecitabinefigure2 (Capecitabinefigure2)

A survival curve graph comparing two treatment groups over time in months since randomization. The dashed line represents the 5-FU + Leucovorin group, and the solid line represents the Capecitabine group. The y-axis shows survival probability, and the x-axis shows months since randomization, with numbers at risk listed below the graph for each time point.*

FDA Label Image

Capecitabinefigure3 (Capecitabinefigure3)

A Kaplan-Meier survival curve chart illustrating estimated probability over time in days. The graph compares two groups: one receiving 5-FU plus Leucovorin (Mayo Regimen) and the other receiving Capecitabine 1250 mg/sqm twice daily intermittently. The Y-axis shows estimated probability from 0 to 1, and the X-axis shows time in days up to 1500, with a marked point at approximately 391 days.*

FDA Label Image

Capecitabinefigure4 (Capecitabinefigure4)

A survival curve chart comparing two treatment groups over time in days. The dashed line represents Docetaxel 100 mg/sqm administered every 3 weeks, and the solid line represents Capecitabine 1250 mg/sqm twice daily intermittently with Docetaxel 75 mg/sqm every 3 weeks. The y-axis shows estimated probability, and the x-axis shows time in days.*

FDA Label Image

Capecitabinefigure5 (Capecitabinefigure5)

A survival curve plot showing estimated probability over time in days for two treatment groups: Docetaxel 100 mg/sqm every 3 weeks (dashed line) and Capecitabine 1250 mg/sqm twice daily intermittent with Docetaxel 75 mg/sqm every 3 weeks (solid line). The graph compares survival probabilities between these groups over approximately 800 days.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.